CD8A and Miyoshi myopathy: Immunopeptidomics research from 2025 studies highlight Galsomes mRNA-LNP vaccines aimed at BCMA neoepitopes, activating CD8+/iNKT cells, outperforming traditional vaccines in MM models [306].